{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.004","upperLimit":"0.322","value":"0.077"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Defined as a partial response or better noted as the objective status on two consecutive evaluations. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab IV over 30 minutes on days 1, 22, 43, 64. Patients also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Cycles with dexamethasone repeat every 84 days for up to 1 year and cycles with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 9 months","title":"Overall Response Percentage","type":"PRIMARY","unitOfMeasure":"percentage of responders"}